Industry Leading Technology
QIAGEN is the leading global provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics.

It all starts with the sample. Genetic material must be extracted from a biological sample and specifically processed before scientists from academia and other industries can work with it. QIAGEN has made the handling of such samples routine. The company has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for the isolation and handling of DNA,
Companies to focus on their service centers to strengthen customer support and provide easier access

Mr. Brendan Green, Project Co-ordinator QIAGEN

The 8th Forbes Global CEO Conference
September 8 - 10, 2008

BIT Life Sciences’ 1st Annual Congress and Expo of Molecular Diagnostics
October 22 - 28, 2008
RNA and proteins - the building blocks of life.  This includes sample collection, separation, and purification as well as open and target specific assays.

Beyond extraction of genetic information from any type of biological sample, QIAGEN's technologies also allow targeted detection of hereditary material.QIAGEN is one of the world's leading providers of molecular diagnostic solutions for human and veterinary disease detection.  QIAGEN assay technologies enable the detection of pathogens as well as the determination of a person's lineage or the origin of traces of biological material found at a crime scene. QIAGEN offers more molecular diagnostic reagents and testing solutions than any other company. 
QIAGEN employs more than 2,700 people in over 30 locations worldwide. Around the globe, QIAGEN helps customers in academic research, diagnostic laboratories, and the pharmaceutical and biotechnology industries achieve outstanding success and breakthroughs. The company's technological leadership and specific know-how drive the markets for sample and assay solutions. When it comes to accessing and analyzing content from biological samples for breakthroughs in biomedical research, drug development and molecular testing, more than 400,000 customers worldwide trust QIAGEN products. QIAGEN makes improvements in life possible.
Protein Technologies : QIAGEN native protein analysis technologies allow you to simplify complexity in applications from gene expression analysis to proteomics. QIAGEN recombinant protein technologies provide integrated, easy-to-use solutions from expression screening through to structural analysis.
RNAi Solutions: An unmatched collection of siRNA, RNAi, and microRNA products for applications such as whole genome screening.
Automated Solutions:QIAGEN provides cutting-edge automation for life science research, clinical research, and in vitro diagnostic laboratories. Complete automated solutions are available to suit your application requirements and daily throughput needs.
Assay Technologies: QIAGEN Quality ensures reliable and sensitive detection for:
  • Gene expression assays
  • Pathogen detection
  • Genetic analysis
  • HLA and haplotyping
QIAGEN and Women's Health
QIAGEN is a global leader in women’s health.  The company offers the only FDA approved and CE marked test which screens for the presence of the high-risk strains of the Human Papillomavirus (HPV).  These high-risk strains have been identified as the primary cause of 99.6% of all cervical cancer.

As an industry leader, QIAGEN is actively involved in raising awareness about the complete preventability of cervical cancer.  These efforts are particularly concentrated in Asia where HPV and HPV testing is still widely unknown and incident rates of cervical cancer are higher.

HPV is the most common of all sexually transmitted diseases.  80% of sexually active women will develop a HPV infection during their lifetime.  While most women are able to clear the infection on their own and present no symptoms, some high-risk strains result in long-term infections.  These long-term HPV infections eventually result in cervical cancer.
Until recently, the healthcare industry has relied on the Pap test to diagnose cervical cancer.  This technique, however, has been proven to be only 50% effective.  QIAGEN’s digene HPV test, when used in conjunction with the Pap, increases the rate of detection to over 90%.

Cervical cancer is the second-most common cancer in women.  Every year 500,000 women are diagnosed with cervical cancer worldwide and 250,000 die.  Widespread adoption of QIAGEN’s digene HPV test could help cut the number of cervical cancer deaths by over half.

Further information about QIAGEN can be found at